As an early stage company, Melanovus Oncology recently launched its efforts to identify potential partners who can help the company grow, and achieve its objectives of bringing effective new drugs to patients with melanoma.
The company is focused on completing its few remaining IND enabling studies, manufacturing, filing its first IND, and beginning a Phase I trial for its lead compound. A phase I trial could begin in the second half of 2014. Opportunities exist for collaboration or partnerships on a broad range of activities, including research, clinical development, commercialization and manufacturing.
Melanovus Oncology employs a capital efficient model and maintains a small core staff of experienced professionals. A network of experienced contract research and manufacturing partners are supporting the company's efforts. Our goal is to maintain operational efficiency, and to maximize the value of each research dollar. As a virtual entity, the company either has direct access to the necessary clinical, business, scientific, and regulatory expertise necessary to successfully commercialize its products.
By focusing on metastatic melanoma as a significant unmet medical need, and by addressing the issue of treatment failures and drug resistance, we believe that our clinical trial program can be efficient and less costly than traditional drug development programs. With positive clinical trial results and accelerated FDA review, a NDA ready package is possible in just 3-5 years.
We would welcome the opportunity to discuss how we might work together to bring new alternatives to patients with melanoma.